JP2015509085A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509085A5 JP2015509085A5 JP2014549632A JP2014549632A JP2015509085A5 JP 2015509085 A5 JP2015509085 A5 JP 2015509085A5 JP 2014549632 A JP2014549632 A JP 2014549632A JP 2014549632 A JP2014549632 A JP 2014549632A JP 2015509085 A5 JP2015509085 A5 JP 2015509085A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- endo180
- antigen
- lipid particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 150000002632 lipids Chemical class 0.000 claims 13
- 102100025351 C-type mannose receptor 2 Human genes 0.000 claims 10
- 101000576898 Homo sapiens C-type mannose receptor 2 Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 235000012000 cholesterol Nutrition 0.000 claims 7
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 3
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 3
- 235000010469 Glycine max Nutrition 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229920001059 synthetic polymer Polymers 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 229920005615 natural polymer Polymers 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- -1 aminopropyl Chemical group 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261582373P | 2012-01-01 | 2012-01-01 | |
| US61/582,373 | 2012-01-01 | ||
| PCT/IL2012/000405 WO2013098813A1 (en) | 2012-01-01 | 2012-12-31 | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509085A JP2015509085A (ja) | 2015-03-26 |
| JP2015509085A5 true JP2015509085A5 (enExample) | 2016-02-18 |
Family
ID=47681993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014549632A Pending JP2015509085A (ja) | 2012-01-01 | 2012-12-31 | 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150216998A1 (enExample) |
| EP (1) | EP2797632A1 (enExample) |
| JP (1) | JP2015509085A (enExample) |
| CN (1) | CN104080480A (enExample) |
| CA (1) | CA2858336A1 (enExample) |
| SG (1) | SG11201403756PA (enExample) |
| WO (1) | WO2013098813A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| IN2014MN01886A (enExample) | 2012-04-18 | 2015-07-10 | Univ Ramot | |
| WO2015013673A1 (en) | 2013-07-25 | 2015-01-29 | Aurasense Therapeutics, Llc | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2015198326A1 (en) | 2014-06-26 | 2015-12-30 | Ramot At Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
| HRP20191400T1 (hr) | 2014-12-24 | 2019-11-15 | Aadigen Llc | Peptidi i nanočestice za unutarstaničnu isporuku molekula |
| EP3247796A4 (en) * | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| JP2016160248A (ja) * | 2015-03-05 | 2016-09-05 | 国立大学法人京都大学 | 糖誘導体、またはその塩、セレクチン結合剤、糖結合体、粒子状キャリア、および輸送方法 |
| FI3303598T3 (fi) | 2015-05-26 | 2025-06-05 | Univ Ramot | Kohdennettuja lipidipartikkeleita nukleiinihappomolekyylien systeemiseen annosteluun leukosyyteille |
| US9868828B2 (en) * | 2015-06-23 | 2018-01-16 | Amolifescience Co., Ltd. | Defined three-dimensional microenvironment for stem cell |
| BR112018015448A2 (en) * | 2016-02-05 | 2018-12-18 | Rigshospitalet | antibody-drug conjugate, pharmaceutical composition, methods for releasing an active agent, treating a disease, inhibiting tumor progression and inhibiting, decreasing or eliminating the metastatic capacity of a tumor, and, kit. |
| WO2018026794A1 (en) * | 2016-08-02 | 2018-02-08 | Curirx Inc. | Methods for the preparation of liposomes |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| ES2711669A1 (es) * | 2017-11-02 | 2019-05-06 | Univ Santiago Compostela | Sistemas de liberacion de farmacos de acido polisialico y metodos |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| WO2022041760A1 (en) * | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4604928A1 (en) * | 2022-10-21 | 2025-08-27 | Georgia Tech Research Corporation | Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof |
| EP4578463A1 (en) * | 2023-12-29 | 2025-07-02 | Oncomatryx Biopharma, S.L. | Endo-180 targeted antibody-drug conjugates |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| CA1264668A (en) | 1984-06-20 | 1990-01-23 | Pieter R. Cullis | Extrusion techniques for producing liposomes |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CA2402613A1 (en) * | 2000-03-29 | 2001-10-04 | Igor Gonda | Cationic liposomes |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| WO2004100759A2 (en) | 2003-05-19 | 2004-11-25 | Quark Biotech, Inc. | Endo 180 receptor for diagnosis and treatment |
| JP2008520600A (ja) * | 2004-11-19 | 2008-06-19 | ノヴォソム アクチェンゲゼルシャフト | 局所投与のための医薬組成物におけるまたはそれに関する改善 |
| JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| WO2007127272A2 (en) | 2006-04-24 | 2007-11-08 | The Cbr Institute For Biomedical Research | Method of producing immunoliposomes and compositions thereof |
| US20100008937A1 (en) | 2006-04-25 | 2010-01-14 | Immune Disease Institute, Inc. | Targeted delivery to leukocytes using non-protein carriers |
| WO2008020435A2 (en) | 2006-08-15 | 2008-02-21 | Quark Pharmaceuticals, Inc | Compositions and methods for treatment of mood disorders |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| TWI373345B (en) * | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| CN104861066B (zh) * | 2009-03-23 | 2018-05-08 | 夸克制药公司 | 治疗癌症和纤维化疾病的化合物组合物和方法 |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| CN102091036A (zh) * | 2011-01-10 | 2011-06-15 | 中国药科大学 | 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途 |
| CN102188713A (zh) * | 2011-05-09 | 2011-09-21 | 中山大学 | 一种肝靶向药物组合物及其制备方法 |
| CN102973506B (zh) * | 2011-09-05 | 2015-06-03 | 中国科学院深圳先进技术研究院 | 阳离子脂质体及其制备方法 |
-
2012
- 2012-12-31 JP JP2014549632A patent/JP2015509085A/ja active Pending
- 2012-12-31 SG SG11201403756PA patent/SG11201403756PA/en unknown
- 2012-12-31 WO PCT/IL2012/000405 patent/WO2013098813A1/en not_active Ceased
- 2012-12-31 EP EP12823110.7A patent/EP2797632A1/en not_active Withdrawn
- 2012-12-31 US US14/367,922 patent/US20150216998A1/en not_active Abandoned
- 2012-12-31 CN CN201280068167.0A patent/CN104080480A/zh active Pending
- 2012-12-31 CA CA2858336A patent/CA2858336A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509085A5 (enExample) | ||
| van der Koog et al. | Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization | |
| Feng et al. | Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His | |
| Zhang et al. | Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona | |
| US8992984B1 (en) | Protocells and their use for targeted delivery of multicomponent cargos to cancer cells | |
| Smyth et al. | Surface functionalization of exosomes using click chemistry | |
| Suk et al. | Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier | |
| Varshney et al. | Targeted delivery of microRNA‐199a‐3p using self‐assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice | |
| US20110269942A1 (en) | Antibodies modified with hydrophobic molecule | |
| JP2012100677A5 (enExample) | ||
| EP3270932A1 (en) | Cross-linked polymer modified nanoparticles | |
| JP2014532071A (ja) | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 | |
| JP2014512409A5 (enExample) | ||
| Nascimento et al. | Lipid-based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs | |
| WO2012094653A2 (en) | Compositions and methods for macromolecular drug delivery | |
| JP2022544289A (ja) | Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物 | |
| JP2022544288A (ja) | ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物 | |
| US20150174265A1 (en) | Reversible masking of pore-forming proteins for macromolecular delivery | |
| Chen et al. | Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG× CD20) | |
| CN110809582B (zh) | 涉及抗pd1抗体试剂的方法以及组合物 | |
| CN117241804A (zh) | 在癌症治疗中slc4a4的抑制 | |
| JP2019533677A (ja) | 細胞傷害性粒子 | |
| CN108883068A (zh) | 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法 | |
| US20130202687A1 (en) | Lipid vectors delivering gene silencers | |
| EP4615416A1 (en) | Self-assembling lipid nanoparticles for targeted delivery of therapeutic agents |